An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan

Clinical Therapeutics

Volumn 20, Issue 3, 1998, Pages 398-409

  Oparil, Suzanne ^a   Guthrie, Robert ^b   Lewin, Andrew J ^c   Marbury, Thomas ^d   Reilly, Karen ^e   Triscari, Joseph ^e   Witcher, Jeffrey A ^e  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c NATIONAL RESEARCH INSTITUTE   (United States)

^d ORLANDO CLINICAL RESEARCH CENTER   (United States)

^e BRISTOL MYERS SQUIBB   (United States)

Author keywords

Angiotensin II receptor blocker; Comparative study; Hypertension; Irbesartan; Losartan; Randomized

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; IRBESARTAN; LOSARTAN;

ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HEADACHE; HEART RATE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; VERTIGO;

EID: 0031901366     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(98)80051-9     Document Type: Article

References (22)

1. 1 subtype angiotensin II receptor antagonist. J Pharmacol Exp Ther. 1993;265:826-834.
2. Munafo A, Christen Y, Nussberger J, et al. Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist. Clin Pharmacol Ther. 1992;51:513-521.
3. Ribstein J, Picard A, Armagnac C, et al. Full antagonism of pressor response to exogenous angiotensin II (AII) by single-dose irbesartan in normotensive subjects. J Hypertens. 1997;15(Suppl 4):S117. Abstract.
4. Christen Y, Waeber B, Nussberger J, et al. Dose-response relationships following oral administration of DuP 753 to normal humans. Am J Hypertens. 1991;4:350S-353S.
5. Christen Y, Waeber B, Nussberger J, et al. Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal volunteers: Inhibition of pressor response to exogenous angiotensin I and II. Circulation. 1991;83:1333-1342.
6. Wong PC, Price WA Jr, Chiu AT, et al. Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: An active metabolite of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther. 1990;255:211-217.
7. Marino MR, Langenbacher KM, Ford NF, Uderman HD. Safety, tolerability, pharmacokinetics and pharmacodynamics of irbesartan after single and multiple doses in healthy male subjects. Clin Pharmacol Ther. 1997;61:207. Abstract.
8. Vachharajani N, Chang S-Y, Shyu WC, et al. Absolute bioavailability of irbesartan, an angiotensin II receptor antagonist, in man. Pharm Res. 1995;12(Suppl):S418. Abstract.
9. Lo M-W, Goldberg MR, McCrea JB, et al. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther. 1995;58:641-649.
10. Kassler-Taub K, Littlejohn T, Elliott W, et al. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan, in mild-to-moderate hypertension. Am J Hypertens. 1998;11: 445-453.
11. Avapro (irbesartan) tablets package insert. Bristol-Myers Squibb, Princeton, New Jersey, 1997.
12. Cozaar® (losartan potassium tablets). Physicians' Desk Reference. Montvale, NJ: Medical Economics Company; 1997: 1668-1670.
13. Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensinconverting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol. 1995;75:793-795.
14. Gradman AH, Arcuri KE, Goldberg AI, et al. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension. 1995;25:1345-1350.
15. Pool JL, Guthrie RM, Littlejohn TW III, et al. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension. Am J Hypertens. 1998; 11:462-470.
16. Fogari R, Ambrosoli S, Corradi L, et al. 24-Hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring. J Hypertens. 1997;15:1511 -1518.
17. Guthrie RM, Saini R, Hannah S, et al. Dose-related reductions in blood pressure with irbesartan, the angiotensin II receptor antagonist. Am J Hypertens. 1997;10 (Part 2):172A. Abstract.
18. Kochar M, Guthrie R, Triscari J, et al. Irbesartan in combination with hydrochlorothiazide in mild-to-moderate hypertension. Am J Hypertens. 1997;10(Part 2):106A. Abstract.
19. 1 receptor antagonist irbesartan in hypertension. Hypertension. 1995;25:22-29.
20. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157: 2413-2446.
21. Brunner HR. The new angiotensin II receptor antagonist, irbesartan. Pharmacokinetic and pharmacodynamic considerations. Am J Hypertens. 1997;10:311S-317S.
22. Reeves RA, Lin C-S, Kassler-Taub K, Pouleur H. Dose-related efficacy of irbesartan for hypertension: An integrated analysis. Hypertension. 1998;31:1311-1316.